Literature DB >> 10352102

Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size.

R L Lees1, J N Heersche.   

Abstract

Several reports indicate that macrophage colony stimulating factor (MCSF) is one of the major factors required for osteoclast proliferation and differentiation. Paradoxically, it has also been reported that MCSF inhibits osteoclastic activity. We therefore decided to investigate in detail the effects of MCSF on resorption and osteoclast formation to try and clarify this issue. Osteoclast-containing cultures were obtained from rabbit long bones and cultured on plastic culture dishes or devitalized bovine bone slices. MCSF (4-400 ng/ml) stimulated osteoclastic bone resorption in a time-dependent manner and at all doses examined. After 48 h of culture in the presence of MCSF, we observed a 2-fold increase in the total area of bone resorbed, as well as a significant increase in the area of bone resorbed per osteoclast and the number of resorption pits per osteoclast. This effect was paralleled by an increase in the number of larger osteoclasts (as determined by the number of nuclei per cell) and an increase in the size and depth of the resorption pits. Since the total number of osteoclasts remained the same, the MCSF-induced increase in resorptive activity appeared to be related to an increase in the average size of the osteoclasts. When resorption was expressed as the amount of bone resorbed per osteoclast nucleus, larger osteoclasts resorbed more per nucleus, suggesting that large osteoclasts, as a population, are more effective resorbers than small osteoclasts. Interestingly, when osteoclasts were plated at one-fifth the standard density, the amount of bone resorbed per osteoclast decreased considerably, indicating that resorptive activity is also affected by cell density of osteoclasts and/or of other cells present. However, at this lower density MCSF still increased osteoclast size and resorption by the same fold increase over control, suggesting that the effect of MCSF was independent of factors related to cell density.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352102     DOI: 10.1359/jbmr.1999.14.6.937

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

1.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

2.  Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function.

Authors:  Hongyan Zhao; Jianhong Gu; Nannan Dai; Qian Gao; Dong Wang; Ruilong Song; Wei Liu; Yan Yuan; Jianchun Bian; Xuezhong Liu; Zongping Liu
Journal:  Cytotechnology       Date:  2015-06-05       Impact factor: 2.058

3.  Runx1-mediated regulation of osteoclast differentiation and function.

Authors:  Do Y Soung; Judith Kalinowski; Sanjeev K Baniwal; Christian E Jacome-Galarza; Baruch Frenkel; Joseph Lorenzo; Hicham Drissi
Journal:  Mol Endocrinol       Date:  2014-02-25

4.  Induction of colony-stimulating factor expression following Staphylococcus or Salmonella interaction with mouse or human osteoblasts.

Authors:  K L Bost; J L Bento; J K Ellington; I Marriott; M C Hudson
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling.

Authors:  María P Menéndez-Gutiérrez; Tamás Rőszer; Lucía Fuentes; Vanessa Núñez; Amelia Escolano; Juan Miguel Redondo; Nora De Clerck; Daniel Metzger; Annabel F Valledor; Mercedes Ricote
Journal:  J Clin Invest       Date:  2015-01-09       Impact factor: 14.808

6.  Self-assembling human skeletal organoids for disease modeling and drug testing.

Authors:  Diana M Abraham; Calvin Herman; Lukasz Witek; Bruce N Cronstein; Roberto L Flores; Paulo G Coelho
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2021-11-27       Impact factor: 3.368

7.  Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.

Authors:  Arkadiusz Z Dudek; Pawel Zwolak; Piotr Jasinski; Kaoru Terai; Nathan J Gallus; Marna E Ericson; Faris Farassati
Journal:  Invest New Drugs       Date:  2007-09-06       Impact factor: 3.850

8.  Runx1 Regulates Myeloid Precursor Differentiation Into Osteoclasts Without Affecting Differentiation Into Antigen Presenting or Phagocytic Cells in Both Males and Females.

Authors:  David N Paglia; Xiaochuan Yang; Judith Kalinowski; Sandra Jastrzebski; Hicham Drissi; Joseph Lorenzo
Journal:  Endocrinology       Date:  2016-06-06       Impact factor: 4.736

9.  An SNX10-dependent mechanism downregulates fusion between mature osteoclasts.

Authors:  Maayan Barnea-Zohar; Sabina E Winograd-Katz; Moran Shalev; Esther Arman; Nina Reuven; Lee Roth; Ofra Golani; Merle Stein; Fadi Thalji; Moien Kanaan; Jan Tuckermann; Benjamin Geiger; Ari Elson
Journal:  J Cell Sci       Date:  2021-05-11       Impact factor: 5.285

10.  Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis.

Authors:  Inês P Perpétuo; Rita Raposeiro; Joana Caetano-Lopes; Elsa Vieira-Sousa; Raquel Campanilho-Marques; Cristina Ponte; Helena Canhão; Mari Ainola; João E Fonseca
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.